Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
87.62
+0.32 (+0.37%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
56
57
Next >
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
August 29, 2024
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots.
Via
Investor's Business Daily
Biotech And Life Science Sector Update Summer Of 2024
August 29, 2024
It’s the slowest week of the year, we are at the market top and most earnings reports are good.
Via
Talk Markets
AstraZeneca Threatens To Move Vaccine Production Amid Reduced State Support
August 23, 2024
AstraZeneca may relocate its vaccine manufacturing site from Merseyside to Philadelphia as the UK government considers slashing state aid from £90 million to £40 million, jeopardizing Britain's life...
Via
Benzinga
Biotech Bull Market: 3 Ways To Play It
August 20, 2024
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally.
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Ozempic And Wegovy Linked to Increased Suicidal Thoughts In Observational Study, But Results Are Contested
August 20, 2024
A recent study in JAMA Network Open raises concerns about a potential link between GLP-1 drugs Ozempic and Wegovy and an increased rate of suicidal thoughts after analyzing World Health Organization...
Via
Benzinga
Is NASDAQ:AZN a Suitable Choice for Quality Investing?
August 14, 2024
Why Quality-Oriented Investors Should Consider NASDAQ:AZN.
Via
Chartmill
Johnson & Johnson Strikes $1.7B Deal To Acquire Heart-Tech Innovator V-Wave
August 20, 2024
Johnson & Johnson to acquire V-Wave for $600 million with potential $1.1 billion in milestone payments. Deal boosts JNJ MedTech's cardiovascular portfolio. Also, FDA approves Rybrevant-Lazcluze combo...
Via
Benzinga
Exposures
Product Safety
10 Health Care Stocks Whale Activity In Today's Session
August 19, 2024
Via
Benzinga
FDA Approves AstraZeneca's Blockbuster Cancer Drug, Imfinzi, In Combination With Chemo For Non-Small Cell Lung Cancer
August 16, 2024
FDA approves AstraZeneca's Imfinzi with chemotherapy for early-stage lung cancer, based on pivotal AEGEAN trial. Imfinzi shows significant event-free survival and pathologic complete response benefits....
Via
Benzinga
Exposures
Product Safety
IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery
August 16, 2024
From
AstraZeneca
Via
Business Wire
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
August 15, 2024
The unveiled prices follow months of back-and-forth negotiation between the government and the companies.
Via
Investor's Business Daily
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US
August 15, 2024
From
AstraZeneca
Via
Business Wire
AstraZeneca's $578M Vaccine Plant In Doubt As UK Government Cuts Funding
August 14, 2024
AstraZeneca is raising concerns that a manufacturing site could be relocated to France, putting an investment in jeopardy.
Via
Benzinga
Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs
August 14, 2024
AstraZeneca, T-Mobile US, and Intuitive Surgical are hitting all-time highs, driven by solid sector performance, robust earnings, and strategic advancements.
Via
MarketBeat
Topics
ETFs
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
August 14, 2024
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Via
InvestorPlace
Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows
August 13, 2024
COVID-19 vaccinations could lower the incidence of heart attacks and strokes, according to a new study by UK universities. The research shows a significant reduction in cardiovascular events among...
Via
Benzinga
Exposures
COVID-19
New European Regulations Could Hinder Rare Disease Treatments, Pharma Industry Raises Concerns Over Stricter Clinical Trial Rules
August 13, 2024
Pharmaceutical companies, researchers, and patient groups are voicing concerns over new EU regulations that could hinder rare disease treatment development by imposing stricter guidelines on medical...
Via
Benzinga
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
August 13, 2024
A recent NIH study reveals no clear diagnostic test for Long Covid, highlighting ongoing challenges in identifying and treating the condition affecting millions of Americans. Researchers continue to...
Via
Benzinga
Exposures
COVID-19
EXCLUSIVE: Penny Stock Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets
August 08, 2024
Conduit Pharmaceuticals has entered an exclusive licensing agreement with AstraZeneca to develop AZD1656, AZD5658, and AZD5904, targeting autoimmune disorders and idiopathic male infertility. Conduit...
Via
Benzinga
Top Analyst Reports For AstraZeneca, TotalEnergies & ConocoPhillips
August 07, 2024
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC, TotalEnergies SE and ConocoPhillips.
Via
Talk Markets
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
August 05, 2024
Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage...
Via
Benzinga
Here's What AstraZeneca's CEO Has to Say About the Weight Loss Drugs Market
August 04, 2024
The winners of today might not compete in the lucrative new segment of tomorrow.
Via
The Motley Fool
Bank Of England Reduces 16-Year High Interest Rates In Divided Decision As Inflation Hits 2%
August 01, 2024
The Bank of England cuts interest rate for first time in over 4 years to 5%, citing inflation below target and emerging economic slack. Pound falls, UK stocks hold steady.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
July 31, 2024
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates.
Via
InvestorPlace
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
July 30, 2024
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns.
Via
Benzinga
Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial
July 29, 2024
From
AstraZeneca
Via
Business Wire
UK Agency Says AstraZeneca's Breast Cancer Drug Enhertu Is Expensive, CEO Pascal Soriot Urges Review Of Drug Pricing Assessment
July 26, 2024
AstraZeneca CEO Pascal Soriot urges the UK government to reassess drug funding after NICE deems Enhertu too costly, highlighting concerns over new methodology affecting advanced cancer treatments and...
Via
Benzinga
3 Surprisingly Underrated Stocks to Buy Right Now
July 26, 2024
These stocks arguably deserve more respect from investors.
Via
The Motley Fool
AstraZeneca Shares Fall Despite EPS Beat and Raised Guidance
July 26, 2024
AstraZeneca beat earnings-per-share (EPS) estimates and raised guidance, but shares still fell. Investors should watch for developments around the drug Enhertu.
Via
MarketBeat
Topics
ETFs
7 Explosive Growth Stocks Set to Soar in 2024
July 25, 2024
These seven explosive growth stocks across various sectors have the potential to deliver substantial returns for investors in 2024.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
56
57
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.